TAZVERIK (tazemetostat) is an EZH2 methyltransferase inhibitor, primarily used to treat specific cancer types with EZH2 mutations, including epithelioid sarcoma and relapsed or refractory follicular lymphoma. It works by inhibiting the EZH2 enzyme, which regulates gene expression through histone methylation, a process that is often disrupted in certain cancers. This drug is FDA-approved under an accelerated approval pathway based on initial clinical data demonstrating a response to treatment. Its continued approval depends on the results of ongoing studies to confirm long-term clinical benefits.

TAZVERIK is administered orally, typically at a dose of 800 mg twice daily, and it is well-suited for patients who have already undergone prior treatments with limited options. However, patients must be monitored for potential adverse reactions, such as hematologic toxicity and lipid abnormalities, which could require dose adjustments.